• Something wrong with this record ?

Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations

D. Andersson, H. Kristiansson, M. Kubista, A. Ståhlberg

. 2021 ; 21 (3) : 299-310. [pub] 20210308

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc22019714

Introduction: Circulating tumor DNA (ctDNA) has become a relevant biomarker in cancer management, allowing tumor assessment through analysis of minimally invasive liquid biopsies. Applications include screening, diagnostics, monitoring of treatment efficacy and detection of minimal residual disease as well as relapse. The potential of ctDNA analysis is significant, but several biological and technical challenges need to be addressed before widespread clinical implementation.Areas covered: Several clinical applications where ctDNA analysis may be beneficial require detection of individual DNA molecules. Consequently, to acquire accurate and informative data the entire workflow from sampling to final data interpretation needs to be optimized. In this review, we discuss the biological and technical challenges of ctDNA analysis and how preanalytical and analytical approaches affect different cancer applications.Expert opinion: While numerous studies have demonstrated the potential of using ctDNA in cancer applications, yet few reports about true clinical utility exist. Despite encouraging data, the sensitivity of ctDNA analyses, i.e. the probability to detect presence of cancer in liquid biopsies, is still an issue. Analysis of multiple mutations in combination with simultaneous assessment of other analytes is one solution. Improved standardization and guidelines will also facilitate the introduction of ctDNA analysis into clinical routine.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019714
003      
CZ-PrNML
005      
20220804135929.0
007      
ta
008      
220720s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14737159.2021.1889371 $2 doi
035    __
$a (PubMed)33683971
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Andersson, Daniel $u Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden $1 https://orcid.org/0000000245646652
245    10
$a Ultrasensitive circulating tumor DNA analysis enables precision medicine: experimental workflow considerations / $c D. Andersson, H. Kristiansson, M. Kubista, A. Ståhlberg
520    9_
$a Introduction: Circulating tumor DNA (ctDNA) has become a relevant biomarker in cancer management, allowing tumor assessment through analysis of minimally invasive liquid biopsies. Applications include screening, diagnostics, monitoring of treatment efficacy and detection of minimal residual disease as well as relapse. The potential of ctDNA analysis is significant, but several biological and technical challenges need to be addressed before widespread clinical implementation.Areas covered: Several clinical applications where ctDNA analysis may be beneficial require detection of individual DNA molecules. Consequently, to acquire accurate and informative data the entire workflow from sampling to final data interpretation needs to be optimized. In this review, we discuss the biological and technical challenges of ctDNA analysis and how preanalytical and analytical approaches affect different cancer applications.Expert opinion: While numerous studies have demonstrated the potential of using ctDNA in cancer applications, yet few reports about true clinical utility exist. Despite encouraging data, the sensitivity of ctDNA analyses, i.e. the probability to detect presence of cancer in liquid biopsies, is still an issue. Analysis of multiple mutations in combination with simultaneous assessment of other analytes is one solution. Improved standardization and guidelines will also facilitate the introduction of ctDNA analysis into clinical routine.
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    12
$a cirkulující nádorová DNA $x genetika $7 D000074141
650    _2
$a lidé $7 D006801
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a individualizovaná medicína $7 D057285
650    _2
$a průběh práce $7 D057188
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Kristiansson, Helena $u Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden $u Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden
700    1_
$a Kubista, Mikael $u Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic $u TATAA Biocenter, Gothenburg, Sweden
700    1_
$a Ståhlberg, Anders $u Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden $u Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden $u Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden $1 https://orcid.org/0000000342430191
773    0_
$w MED00174421 $t Expert review of molecular diagnostics $x 1744-8352 $g Roč. 21, č. 3 (2021), s. 299-310
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33683971 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135923 $b ABA008
999    __
$a ok $b bmc $g 1823073 $s 1170957
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 21 $c 3 $d 299-310 $e 20210308 $i 1744-8352 $m Expert review of molecular diagnostics $n Expert Rev Mol Diagn $x MED00174421
LZP    __
$a Pubmed-20220720
Back

Find record

Citation metrics

Archiving options